Table 1 Characteristics of 12 randomised controlled trials of vitamin D supplements in populations with mean/median 25OHD < 25 nmol/L and clinical endpoints reported in abstract
Study | Clinical endpoint | Endpoint type | Study Size (N) | 25OHD Assay | Mean/Median 25OHD (SD) (nmol/L)a | Result of Trialb |
|---|---|---|---|---|---|---|
Brooke 1980 [44] | Newborn outcomes | Secondary | 126 | CBP | 11 (1) | Benefit |
Chapuy 1994 [21] | Fracture | Primary | 3270 | CBP | 20 (14) | Benefit |
Pfeifer 2000 [45] | Risk of fall | Secondary | 148 | Nicholls | 19 (10) | Neutral |
Chapuy 2002 [46] | Fracture | Secondary | 583 | Incstar | 22 (16) | Neutral |
Bischoff 2003 [47] | Risk of fall | Primary | 122 | Nicholls | 23 (N/A) | Neutral |
Martineau 2011 [48] | Tuberculosis sputum culture conversion | Primary | 126 | LCMS/MS | 21 (20) | Neutral |
Mosayebi 2011 [49] | Multiple sclerosis disability score | Primary | 59 | IDS | 25 (7) | Neutral |
Amestejani 2012 [50] | Atopic dermatitis | Primary | 60 | Biosource | 24 (5) | Benefit |
Schreuder 2012 [51] | Pain | Primary | 84 | Diasorin | 20 (10) | Neutral |
Mozaffari-Khosravi 2013 [52] | Depression score | Primary | 120 | IDS | 23 (N/A) | Benefit |
Hossain 2014 [53] | Pregnancy outcomes | Primary | 200 | Immunoassay | 13 (N/A) | Neutral |
Bhan 2015 [54] | All-cause mortality | Secondary | 105 | LCMS/MS | 22 (7) | Neutral |